Upscaling: the growth factor

The art of upscaling industrial biotech – the topic is not just the cover story, but is picked up in several articles in this issue. Many industrial biotech projects compete directly with traditional petro-based production processes. And many that start out in publicly funded industrial biotechnology  start-up ecosystems in Europe fail because they’re simply not at first competitive when it comes  to costs. The petrochemicals industry has had decades to optimise both production processes  and return on investment in existing plants. Now a French-German-Belgian project is showing how those advantages dwindle when a bioeconomy plant is up and running.

In this issue:

• The Trump factor – European Biotechnology takes a closer look at the situation as of June 2025.
• Start-up and scale-up companies in EC’s focus
• EMA to simplify EU market authorisation rules for biosimilars
• Industry protests against Council-adopted EU pharma package
• Interview with Josko Bobanovic, Partner Industrial Biotech Strategy at Sofinnova Partners – The next Pharma model is key in bioeconomy too
• European Biotech Stock market with analyst commentary
• Regulatory affairs – update of ongoing clinical trials
• Quality Management in Life Sciences – today, it must do much more than ensure compliance
• Why life sciences leaders need more than science
• Science & Technology, Regional news, Biopeople, news from BIOTECH Austria, Society for Laboratory Automation and Screening (SLAS) and the Young European Biotech Network
• BioFairs Compass – Guide to Life Sciences Events in 2025
• Focus: Techparks/Bioengineering
• Special: Lab automation – New Modalities